-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121

Benzinga·11/06/2026 16:12:39
Listen to the news
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $119 to $121.